Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Cathepsin C : structure, function, and pharmacological targeting
ID
Stojkovska, Milena
(
Author
),
ID
Novinec, Marko
(
Author
)
PDF - Presentation file,
Download
(1,89 MB)
MD5: 10021AB84E4999F03112C483601D1288
URL - Source URL, Visit
https://rdodjournal.com/article/view/5974
Image galllery
Abstract
Cathepsin C is a papain-like cysteine peptidase known primarily for its involvement in the activation of serine peptidases in neutrophils and other immune cells. Its critical role in this process qualifies cathepsin C as a target for the treatment of inflammatory diseases, and its most advanced inhibitor, brensocatib (Insmed), is currently in phase 3 clinical trials for the treatment of non-cystic fibrosis bronchiectasis. Beyond neutrophils, its importance is highlighted by loss-of-function mutations that cause the recessively inherited Papillon-Lefèvre syndrome. At the molecular level, cathepsin C has several structural and functional features that set it apart from other members of the family and enable its selective targeting. It possesses dipeptidyl-peptidase activity (its other common name is dipeptidyl-peptidase I) due to the presence of an additional exclusion domain that also controls its stepwise tetramerization during maturation. In this review article, we summarize the current state of the art regarding the biochemical properties of cathepsin C, its physiological and pathological roles in neutrophils and beyond, and recent advances in the development and evaluation of cathepsin C inhibitors.
Language:
English
Keywords:
dipeptidyl-peptidase I
,
DPPI
,
cysteine catepsin
,
bronchiectasis
,
brensocatib
Work type:
Article
Typology:
1.02 - Review Article
Organization:
FKKT - Faculty of Chemistry and Chemical Technology
Publication status:
Published
Publication version:
Version of Record
Publication date:
01.01.2023
Year:
2023
Number of pages:
Str. 1-17
Numbering:
Vol. 2, iss. 3, art. 14
PID:
20.500.12556/RUL-148208
UDC:
547.112
ISSN on article:
2771-2893
DOI:
10.20517/rdodj.2023.09
COBISS.SI-ID:
160356355
Publication date in RUL:
02.08.2023
Views:
779
Downloads:
58
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Rare disease and orphan drugs journal
Shortened title:
Rare dis. orphan drug j.
Publisher:
OAE Publishing Inc.
ISSN:
2771-2893
COBISS.SI-ID:
160332035
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Secondary language
Language:
Slovenian
Keywords:
dipeptidil-peptidaza I
,
DPPI
,
cisteinski katepsin
,
bronhiektazija
,
brensocatib
Projects
Funder:
ARRS - Slovenian Research Agency
Project number:
N1-0211
Name:
Uvedba kooperativnosti v peptidaze za izboljšanje njihove aktivnosti in uravnavanja
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0179
Name:
Napredna organska sinteza in kataliza
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back